Justices Told Fraud Tainted Vascepa Patent Invalidations
A group made largely of Amarin shareholders has asked the U.S. Supreme Court to override the invalidation of patents covering the company's blockbuster cardiovascular drug Vascepa, claiming both a Nevada federal...To view the full article, register now.
Already a subscriber? Click here to view full article